Literature DB >> 19559599

Neutralizing ebolavirus: structural insights into the envelope glycoprotein and antibodies targeted against it.

Jeffrey E Lee1, Erica Ollmann Saphire.   

Abstract

The ebolavirus (EBOV) envelope glycoprotein (GP) is solely responsible for viral attachment to, fusion with, and entry of new host cells, and consequently is a major target of vaccine design efforts. Recently determined crystal structures of key antibodies in complex with their EBOV epitopes have provided insights into the molecular architecture of GP and defined likely hotspots for viral neutralization. In this review, we discuss the structural basis for antibody-mediated neutralization of ebolavirus and its implications for novel therapeutic or vaccine strategies.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19559599      PMCID： PMC2759674          DOI： 10.1016/j.sbi.2009.05.004

Source DB:  PubMed          Journal:  Curr Opin Struct Biol        ISSN： 0959-440X            Impact factor:   6.809


  53 in total

1.  Ebola virus can be effectively neutralized by antibody produced in natural human infection.

Authors:  T Maruyama; L L Rodriguez; P B Jahrling; A Sanchez; A S Khan; S T Nichol; C J Peters; P W Parren; D R Burton
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

Review 2.  The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis.

Authors:  H Feldmann; V E Volchkov; V A Volchkova; H D Klenk
Journal:  Arch Virol Suppl       Date:  1999

3.  Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody.

Authors:  Paul W H I Parren; Tom W Geisbert; Toshiaki Maruyama; Peter B Jahrling; Dennis R Burton
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

4.  Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor.

Authors:  Jens H Kuhn; Sheli R Radoshitzky; Alexander C Guth; Kelly L Warfield; Wenhui Li; Martin J Vincent; Jonathan S Towner; Stuart T Nichol; Sina Bavari; Hyeryun Choe; M Javad Aman; Michael Farzan
Journal:  J Biol Chem       Date:  2006-04-04       Impact factor: 5.157

5.  Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein.

Authors:  Kathryn Schornberg; Shutoku Matsuyama; Kirsten Kabsch; Sue Delos; Amy Bouton; Judith White
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

6.  Comprehensive analysis of ebola virus GP1 in viral entry.

Authors:  Balaji Manicassamy; Jizhen Wang; Haiqing Jiang; Lijun Rong
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

7.  Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection.

Authors:  Kartik Chandran; Nancy J Sullivan; Ute Felbor; Sean P Whelan; James M Cunningham
Journal:  Science       Date:  2005-04-14       Impact factor: 47.728

8.  Core structure of the envelope glycoprotein GP2 from Ebola virus at 1.9-A resolution.

Authors:  V N Malashkevich; B J Schneider; M L McNally; M A Milhollen; J X Pang; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

9.  Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.

Authors:  Nancy J Sullivan; Thomas W Geisbert; Joan B Geisbert; Devon J Shedlock; Ling Xu; Laurie Lamoreaux; Jerome H H V Custers; Paul M Popernack; Zhi-Yong Yang; Maria G Pau; Mario Roederer; Richard A Koup; Jaap Goudsmit; Peter B Jahrling; Gary J Nabel
Journal:  PLoS Med       Date:  2006-05-16       Impact factor: 11.069

10.  Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation.

Authors:  Hsien-Sheng Yin; Xiaolin Wen; Reay G Paterson; Robert A Lamb; Theodore S Jardetzky
Journal:  Nature       Date:  2006-01-05       Impact factor: 49.962
View more
  42 in total

1.  Structural and Functional Studies on the Marburg Virus GP2 Fusion Loop.

Authors:  Nina Liu; Yisong Tao; Michael D Brenowitz; Mark E Girvin; Jonathan R Lai
Journal:  J Infect Dis       Date:  2015-03-18       Impact factor: 5.226

2.  Immunization-Elicited Broadly Protective Antibody Reveals Ebolavirus Fusion Loop as a Site of Vulnerability.

Authors:  Xuelian Zhao; Katie A Howell; Shihua He; Jennifer M Brannan; Anna Z Wec; Edgar Davidson; Hannah L Turner; Chi-I Chiang; Lin Lei; J Maximilian Fels; Hong Vu; Sergey Shulenin; Ashley N Turonis; Ana I Kuehne; Guodong Liu; Mi Ta; Yimeng Wang; Christopher Sundling; Yongli Xiao; Jennifer S Spence; Benjamin J Doranz; Frederick W Holtsberg; Andrew B Ward; Kartik Chandran; John M Dye; Xiangguo Qiu; Yuxing Li; M Javad Aman
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

Review 3.  Achieving cross-reactivity with pan-ebolavirus antibodies.

Authors:  Liam B King; Jacob C Milligan; Brandyn R West; Sharon L Schendel; Erica Ollmann Saphire
Journal:  Curr Opin Virol       Date:  2019-03-15       Impact factor: 7.090

4.  Cell entry by a novel European filovirus requires host endosomal cysteine proteases and Niemann-Pick C1.

Authors:  Melinda Ng; Esther Ndungo; Rohit K Jangra; Yingyun Cai; Elena Postnikova; Sheli R Radoshitzky; John M Dye; Eva Ramírez de Arellano; Ana Negredo; Gustavo Palacios; Jens H Kuhn; Kartik Chandran
Journal:  Virology       Date:  2014-10-11       Impact factor: 3.616

Review 5.  The structural basis for filovirus neutralization by monoclonal antibodies.

Authors:  Liam B King; Brandyn R West; Sharon L Schendel; Erica Ollmann Saphire
Journal:  Curr Opin Immunol       Date:  2018-06-22       Impact factor: 7.486

6.  A new strategy for full-length Ebola virus glycoprotein expression in E.coli.

Authors:  Junjie Zai; Yinhua Yi; Han Xia; Bo Zhang; Zhiming Yuan
Journal:  Virol Sin       Date:  2016-12-16       Impact factor: 4.327

7.  Cathepsin cleavage potentiates the Ebola virus glycoprotein to undergo a subsequent fusion-relevant conformational change.

Authors:  Matthew Brecher; Kathryn L Schornberg; Sue E Delos; Marnie L Fusco; Erica Ollmann Saphire; Judith M White
Journal:  J Virol       Date:  2011-10-26       Impact factor: 5.103

Review 8.  Structure-based vaccine design in HIV: blind men and the elephant?

Authors:  Robert Pejchal; Ian A Wilson
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

9.  Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein.

Authors:  Masahiro Kajihara; Andrea Marzi; Eri Nakayama; Takeshi Noda; Makoto Kuroda; Rashid Manzoor; Keita Matsuno; Heinz Feldmann; Reiko Yoshida; Yoshihiro Kawaoka; Ayato Takada
Journal:  J Virol       Date:  2012-10-03       Impact factor: 5.103

10.  Novel mutations in Marburg virus glycoprotein associated with viral evasion from antibody mediated immune pressure.

Authors:  Masahiro Kajihara; Eri Nakayama; Andrea Marzi; Manabu Igarashi; Heinz Feldmann; Ayato Takada
Journal:  J Gen Virol       Date:  2013-01-03       Impact factor: 3.891
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.